Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)
Clinical trial NCT04443907 · TERMINATED
Trial details
- NCT number
- NCT04443907
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-25
- Primary completion
- 2025-01-06
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.